Cardiology | Antiarrhythmic Drug Guide | Class Ia | Disopyramide
||No IV form
||< 2 yr.: 23-33 mg/kg/day (mean 30)
2-10 yr.: 9-24 mg/kg/day (mean 20)
>10 yr.: 5-13 mg/kg/day (mean 8)
divided q 6 hours, or q 12 hours for CR forms.
Maximum 1200 mg/day.
||2-5 ug/ml, poorly correlated with efficacy
||Peak levels at 0.5-3 hours after oral dose. (3.4-4.0 hours after controlled release form). Nonlinear kinetics due to protein binding. Elimination half-life 5-6 hours at therapeutic levels. Large Vd in children.
||Causes significant decreases in contractility! In renal failure, active metabolite (NMD) accumulates, which is even more anticholinergic than parent compound.
||None with digoxin.
Atenolol decreases clearance and is synergistic in decreasing cardiac output. (Probably true for allbeta blockers).
Phenytoin increases clearance and decreases levels.
||Norpace capsules: 100, 150 mg
Norpace CR: controlled release capsules: 100, 150 mg
|FDA approval in children
Return to Antiarrhythmic Drug Guide page